Xeris Biopharma (NASDAQ:XERS) Issues Earnings Results, Misses Expectations By $0.19 EPS

Xeris Biopharma (NASDAQ:XERS) announced its quarterly earnings results on Thursday. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of $0.01 by ($0.19), FiscalAI reports. The firm had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Second-quarter revenue reached a record $92.1 million, with net product revenue up 34% year over year to $91 million; adjusted EBITDA increased more than 50% to $19.3 million.
• RECORLEV revenue surged 81% to $56.8 million, supported by record referrals, new patient starts, and prescriber growth. Management expects the expanded commercial team to contribute further in the second half.
• Xeris raised and narrowed full-year 2026 revenue guidance to $385 million-$390 million, citing sustained portfolio momentum and an expected rebound in Gvoke, while KEVEYIS received a patent allowance that could extend protection through at least 2039.
• The company fully retired its $34 million of convertible debt in July, eliminating approximately $3 million in annual interest expense and simplifying the balance sheet, although the transaction generated a one-time, non-cash GAAP charge of about $31 million in the second quarter.
• Xeris plans to increase full-year SG&A by approximately $50 million and R&D by $25 million versus 2025, primarily to support RECORLEV expansion and the planned year-end Phase III start for XP-8121; management expects R&D spending to rise further as the trial ramps in 2027.

Xeris Biopharma Trading Up 7.7%

NASDAQ:XERS traded up $0.57 during trading hours on Friday, hitting $7.93. The company had a trading volume of 2,251,719 shares, compared to its average volume of 1,886,183. The company has a market capitalization of $1.37 billion, a PE ratio of 132.17 and a beta of 0.66. The stock has a 50-day moving average price of $7.64 and a 200 day moving average price of $6.79. Xeris Biopharma has a 52 week low of $5.25 and a 52 week high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 2.12 and a quick ratio of 1.50.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.80.

Insiders Place Their Bets

In other news, insider Kevin Mcculloch sold 90,000 shares of Xeris Biopharma stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00. Following the sale, the insider owned 1,691,126 shares of the company’s stock, valued at approximately $13,579,741.78. The trade was a 5.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Steven Pieper sold 27,600 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00. Following the transaction, the insider owned 1,366,053 shares in the company, valued at $11,638,771.56. This represents a 1.98% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 266,499 shares of company stock worth $1,996,417. Company insiders own 4.35% of the company’s stock.

Institutional Trading of Xeris Biopharma

Several large investors have recently bought and sold shares of XERS. Royal Bank of Canada raised its position in shares of Xeris Biopharma by 1,411.2% in the 1st quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Xeris Biopharma by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock valued at $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC grew its stake in Xeris Biopharma by 19.0% in the first quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the period. Goldman Sachs Group Inc. grew its stake in Xeris Biopharma by 75.4% in the first quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares during the period. Finally, Caxton Associates LLP bought a new position in Xeris Biopharma in the first quarter worth $170,000. 42.75% of the stock is owned by institutional investors.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.